Date published: 2025-10-2

1-800-457-3801

SCBT Portrait Logo
Seach Input

GIPC Inhibitors

The class of GIPC inhibitors comprises a diverse array of chemical compounds that exert their effects either directly on GIPC or indirectly by influencing key signaling pathways and cellular processes associated with GIPC functionality. These inhibitors have the potential to modulate GIPC-related functions and cellular responses through their specific interactions with well-defined biochemical and cellular pathways. One prominent group of GIPC inhibitors includes compounds that target the PI3K/AKT pathway, such as Rapamycin, Wortmannin, and LY294002. These inhibitors disrupt the intricate signaling cascade of PI3K/AKT, leading to downstream alterations that may impact GIPC-mediated cellular processes. By interfering with this pathway, these compounds showcase the interconnectedness of intracellular signaling networks and GIPC functionality. Additionally, GIPC inhibitors like PD98059, U0126, and Trametinib operate through the MAPK/ERK pathway, disrupting signaling cascades that intersect with GIPC-related processes. The intricate modulation of the MAPK/ERK pathway by these inhibitors highlights the potential for indirect regulation of GIPC and the complexity of cellular responses influenced by GIPC.

Stress-related pathways are also targeted by GIPC inhibitors such as SB203580, JNK Inhibitor VIII, and SP600125. These compounds showcase the interplay between stress signaling and GIPC-mediated functions, emphasizing the diverse cellular responses modulated by GIPC in response to stress. Furthermore, GIPC inhibitors like SB431542 and TPCA-1 act on TGF-β and NF-κB pathways, respectively. The indirect modulation of GIPC through these pathways underscores the intricate regulatory networks that influence GIPC-mediated cellular processes, including those related to TGF-β signaling and NF-κB-mediated responses. In summary, the class of GIPC inhibitors demonstrates the complexity of cellular regulation by targeting specific pathways. These inhibitors, whether direct or indirect, offer valuable insights into the intricate web of signaling cascades that intersect with GIPC functionality.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

Rapamycin, an mTOR inhibitor, disrupts the PI3K/AKT/mTOR pathway. It indirectly affects GIPC by modulating downstream signaling, altering cellular processes and potentially inhibiting GIPC-mediated functions.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$66.00
$219.00
$417.00
97
(3)

As a PI3K inhibitor, Wortmannin disrupts the PI3K/AKT pathway. Its influence on this pathway can indirectly impact GIPC, potentially modulating its cellular functions and interactions.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

LY294002, a PI3K inhibitor, targets the PI3K/AKT pathway. Its inhibition of PI3K can lead to indirect modulation of GIPC, affecting cellular processes associated with GIPC function.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$88.00
$342.00
284
(5)

SB203580, a p38 MAPK inhibitor, influences stress-related pathways. Through its effect on stress signaling, it may indirectly modulate GIPC, altering cellular responses and potentially impacting GIPC-mediated functions.

SB 431542

301836-41-9sc-204265
sc-204265A
sc-204265B
1 mg
10 mg
25 mg
$80.00
$212.00
$408.00
48
(1)

SB431542, a TGF-β receptor inhibitor, disrupts TGF-β signaling. Its indirect influence on GIPC may occur through modulation of TGF-β-related pathways, affecting cellular processes associated with GIPC function.

JNK Inhibitor VIII

894804-07-0sc-202673
5 mg
$267.00
2
(1)

JNK Inhibitor VIII inhibits the JNK pathway. By disrupting this stress-related pathway, it may indirectly modulate GIPC, influencing cellular responses and potentially impacting GIPC-mediated functions.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

SP600125, a JNK inhibitor, affects stress-related signaling pathways. Its impact on stress responses can indirectly influence GIPC, potentially modulating cellular processes associated with GIPC function.

Bemcentinib

1037624-75-1sc-507363
10 mg
$900.00
(0)

R428, a focal adhesion kinase (FAK) inhibitor, targets FAK signaling. Its inhibition of FAK can indirectly impact GIPC, potentially modulating cellular processes associated with GIPC function and FAK signaling.

Trametinib

871700-17-3sc-364639
sc-364639A
sc-364639B
5 mg
10 mg
1 g
$112.00
$163.00
$928.00
19
(1)

Trametinib, a MEK inhibitor, disrupts the MAPK/ERK pathway. Its influence on this pathway can indirectly affect GIPC, leading to alterations in downstream signaling and potential modulation of GIPC-mediated cellular functions.

IKK-2 Inhibitor IV

507475-17-4sc-203083
500 µg
$130.00
12
(1)

TPCA-1, an IKK-2 inhibitor, targets the NF-κB pathway. Through its impact on NF-κB signaling, it may indirectly modulate GIPC, affecting cellular processes associated with GIPC function and NF-κB-mediated responses.